NASDAQ:ITOS iTeos Therapeutics (ITOS) Stock Forecast, Price & News $11.11 -0.31 (-2.71%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$11.04▼$11.5550-Day Range$11.11▼$14.6052-Week Range$11.03▼$23.00Volume185,729 shsAverage Volume321,826 shsMarket Capitalization$397.52 millionP/E RatioN/ADividend YieldN/APrice Target$36.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media iTeos Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside227.0% Upside$36.33 Price TargetShort InterestBearish5.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.95Based on 3 Articles This WeekInsider TradingSelling Shares$5.69 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.26) to ($5.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector386th out of 962 stocksBiological Products, Except Diagnostic Industry58th out of 160 stocks 3.5 Analyst's Opinion Consensus RatingiTeos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.33, iTeos Therapeutics has a forecasted upside of 227.0% from its current price of $11.11.Amount of Analyst CoverageiTeos Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.53% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iTeos Therapeutics has recently increased by 5.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldiTeos Therapeutics does not currently pay a dividend.Dividend GrowthiTeos Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ITOS. Previous Next 2.7 News and Social Media Coverage News SentimentiTeos Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for iTeos Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for ITOS on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iTeos Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,691,000.00 in company stock.Percentage Held by Insiders10.20% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for iTeos Therapeutics are expected to decrease in the coming year, from ($3.26) to ($5.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iTeos Therapeutics is -13.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iTeos Therapeutics is -13.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiTeos Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About iTeos Therapeutics (NASDAQ:ITOS) StockIteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.Read More ITOS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITOS Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Large Increase in Short InterestSeptember 6, 2023 | finance.yahoo.comiTeos to Participate in Upcoming Investor ConferencesSeptember 26, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 27, 2023 | finance.yahoo.comBOXER CAPITAL, LLC Reduces Stake in ITeos Therapeutics IncAugust 25, 2023 | seekingalpha.comiTeos Therapeutics And The TIGIT Ticket To Cancer's DownfallAugust 23, 2023 | bizjournals.comWatertown biotech shares spike after accidental data publication at RocheAugust 23, 2023 | markets.businessinsider.comWhy ITeos Therapeutics (ITOS) Stock Is Moving HigherAugust 23, 2023 | finance.yahoo.comWhy Roche's Accidental Cancer Update Boosted Iteos 41% And Arcus 28%September 26, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 9, 2023 | msn.comHC Wainwright & Co. Maintains ITeos Therapeutics (ITOS) Buy RecommendationAugust 9, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on iTeos Therapeutics (ITOS)August 8, 2023 | finanznachrichten.deiTeos Therapeutics Inc.: iTeos Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAugust 8, 2023 | finance.yahoo.comiTeos Reports Second Quarter 2023 Financial Results and Provides Business UpdatesJune 4, 2023 | seekingalpha.comiTeos Therapeutics: Trading Under Cash ValueMay 13, 2023 | finance.yahoo.comBroker Revenue Forecasts For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Are Surging HigherMay 11, 2023 | markets.businessinsider.comiTeos Therapeutics (ITOS) Gets a Buy from H.C. WainwrightMay 11, 2023 | finance.yahoo.comiTeos Therapeutics First Quarter 2023 Earnings: Beats ExpectationsMay 10, 2023 | finance.yahoo.comITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue EstimatesMay 10, 2023 | finanznachrichten.deiTeos Therapeutics Inc.: iTeos Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 10, 2023 | finance.yahoo.comiTeos Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 5, 2023 | finance.yahoo.comiTeos Therapeutics (NASDAQ:ITOS) shareholders have endured a 46% loss from investing in the stock a year agoMarch 31, 2023 | seekingalpha.comiTeos Therapeutics (ITOS) Investor Presentation - SlideshowMarch 23, 2023 | finance.yahoo.comDown More Than 50%: 2 ‘Strong Buy’ Stocks That Are Too Cheap to IgnoreMarch 21, 2023 | finance.yahoo.comTake Care Before Jumping Onto iTeos Therapeutics, Inc. (NASDAQ:ITOS) Even Though It's 25% CheaperMarch 17, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for iTeos Therapeutics (ITOS)March 17, 2023 | finance.yahoo.comTime To Worry? Analysts Are Downgrading Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) OutlookMarch 16, 2023 | msn.comLooking Into ITeos Therapeutics's Return On Invested CapitalSee More Headlines Receive ITOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ITOS Company Calendar Last Earnings8/08/2023Today9/25/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ITOS CUSIPN/A CIK1808865 Webwww.iteostherapeutics.com Phone339-217-0161FaxN/AEmployees125Year FoundedN/APrice Target and Rating Average Stock Price Forecast$36.33 High Stock Price Forecast$44.00 Low Stock Price Forecast$32.00 Forecasted Upside/Downside+226.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$96.65 million Net Margins9.02% Pretax Margin-31.00% Return on Equity-4.42% Return on Assets-3.83% Debt Debt-to-Equity RatioN/A Current Ratio20.47 Quick Ratio20.47 Sales & Book Value Annual Sales$267.63 million Price / Sales1.49 Cash Flow$2.62 per share Price / Cash Flow4.24 Book Value$18.65 per share Price / Book0.60Miscellaneous Outstanding Shares35,780,000Free Float32,132,000Market Cap$397.87 million OptionableNot Optionable Beta1.20 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Michel Detheux Ph.D. (Age 57)Pres, CEO & Director Comp: $922.38kMr. Matthew A. Call M.B.A. (Age 50)Chief Operating Officer Comp: $638.55kMr. Matthew Gall (Age 46)Chief Financial Officer Dr. Yvonne McGrath Ph.D. (Age 49)Chief Scientific Officer Mr. Ryan BakerHead of Investor RelationsMs. Adi OsovskyVP & Head of LegalMr. Phillipe BrantegemVice-Pres of HRMore ExecutivesKey CompetitorsCullinan OncologyNASDAQ:CGEMCoherus BioSciencesNASDAQ:CHRSIcosavaxNASDAQ:ICVXAgenusNASDAQ:AGENScholar RockNASDAQ:SRRKView All CompetitorsInsiders & InstitutionsBarclays PLCBought 57,924 shares on 9/21/2023Ownership: 0.880%Boxer Capital, LlcSold 350,000 sharesTotal: $5.69 M ($16.26/share)Virginia Retirement Systems ET ALBought 42,000 shares on 8/22/2023Ownership: 0.117%California State Teachers Retirement SystemBought 2,730 shares on 8/21/2023Ownership: 0.080%Nuveen Asset Management LLCSold 21,571 shares on 8/16/2023Ownership: 0.212%View All Insider TransactionsView All Institutional Transactions ITOS Stock - Frequently Asked Questions Should I buy or sell iTeos Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ITOS shares. View ITOS analyst ratings or view top-rated stocks. What is iTeos Therapeutics' stock price forecast for 2023? 3 brokers have issued 1 year price targets for iTeos Therapeutics' shares. Their ITOS share price forecasts range from $32.00 to $44.00. On average, they expect the company's share price to reach $36.33 in the next year. This suggests a possible upside of 226.7% from the stock's current price. View analysts price targets for ITOS or view top-rated stocks among Wall Street analysts. How have ITOS shares performed in 2023? iTeos Therapeutics' stock was trading at $19.53 at the start of the year. Since then, ITOS stock has decreased by 43.1% and is now trading at $11.12. View the best growth stocks for 2023 here. Are investors shorting iTeos Therapeutics? iTeos Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,620,000 shares, an increase of 5.9% from the August 15th total of 1,530,000 shares. Based on an average daily volume of 425,900 shares, the short-interest ratio is currently 3.8 days. Approximately 5.5% of the company's stock are short sold. View iTeos Therapeutics' Short Interest. When is iTeos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our ITOS earnings forecast. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its earnings results on Tuesday, August, 8th. The company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.07. iTeos Therapeutics had a net margin of 9.02% and a negative trailing twelve-month return on equity of 4.42%. What ETFs hold iTeos Therapeutics' stock? ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of iTeos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA). When did iTeos Therapeutics IPO? (ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is iTeos Therapeutics' stock symbol? iTeos Therapeutics trades on the NASDAQ under the ticker symbol "ITOS." Who are iTeos Therapeutics' major shareholders? iTeos Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.08%), State Street Corp (4.37%), Goldman Sachs Group Inc. (1.80%), Candriam S.C.A. (1.71%), 683 Capital Management LLC (1.63%) and Dimensional Fund Advisors LP (1.62%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath. View institutional ownership trends. How do I buy shares of iTeos Therapeutics? Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is iTeos Therapeutics' stock price today? One share of ITOS stock can currently be purchased for approximately $11.12. How much money does iTeos Therapeutics make? iTeos Therapeutics (NASDAQ:ITOS) has a market capitalization of $397.87 million and generates $267.63 million in revenue each year. The company earns $96.65 million in net income (profit) each year or ($0.80) on an earnings per share basis. How many employees does iTeos Therapeutics have? The company employs 125 workers across the globe. How can I contact iTeos Therapeutics? The official website for the company is www.iteostherapeutics.com. The company can be reached via phone at 339-217-0161 or via email at ir@iteostherapeutics.com. This page (NASDAQ:ITOS) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.